Dyne Therapeutics Faces Overhang Ahead of Data Readout, Oppenheimer Says
MT Newswires Live
Oct 10
Dyne Therapeutics' (DYN) new data supported DYNE-101's treatment effect on myotonic dystrophy type 1 patients but a key overhang remains, Oppenheimer said in a note Friday.
"We view powering of the pivotal study (mid-2026 readout) as a key overhang given the small cohort size and statistical variability," the report said.
Following a recent stock rally, Oppenheimer analysts said they are stepping to the sidelines based on valuation ahead of pivotal readout later this year from DYN-251 in duchenne muscular dystrophy, where they remain "cautious around safety."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.